<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917163</url>
  </required_header>
  <id_info>
    <org_study_id>SES/RCT/01</org_study_id>
    <nct_id>NCT00917163</nct_id>
  </id_info>
  <brief_title>SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent</brief_title>
  <official_title>A Randomized Comparison of the Supralimus® Stent With the Xience V™ Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahajanand Medical Technologies Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardialysis BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahajanand Medical Technologies Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of Series III Run-In Trial is to compare the performance and efficacy of the
      Supralimus® sirolimus-eluting stent with the Xience V™ everolimus-eluting stent with respect
      to in-stent luminal late loss at 9 months as assessed by off-line QCA. Ninety percent power
      to reject the null hypothesis that the Supralimus® stent is inferior to Xience V™ in favor of
      the alternative hypothesis that the Supralimus® stent is not inferior to Xience V™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Series III Run-In is a prospective, multi-center, randomized, single-blind (patient-blind),
      non-inferiority trial to be conducted at approx. 35 interventional cardiology centers in
      India, Brazil, Argentina, Thailand and Saudi Aurabia. A total of 360 will be randomized on a
      2:1 basis to either the Supralimus® (sirolimus-eluting) stent or the Xience V™
      (everolimus-eluting) stent.

      In selected sites, IVUS will also be recorded in these patients (maximum of 60 IVUS patients
      in total), at baseline (post-procedure) and at 9-month follow-up.

      All patients will be followed clinically for up to 5 years after stent implantation. Repeat
      angiography will be performed in all patients at 9 months after the index procedure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to unavoidable circumstances relating to logistic issues and regulatory processes in
    various countries causing unacceptable delays.
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent luminal late loss at 9 months after stent implantation (off-line QCA).</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PROCEDURAL: Pre-procedure Syntax Score (by off-line visual assessment), Procedural success rate, Device success rate</measure>
    <time_frame>Hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANGIOGRAPHIC : Minimal lumen diameter (MLD), % diameter stenosis, In-segment late loss, Proximal late loss, Distal late loss, Binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVUS (in a subset of patients): Minimal lumen area, Vessel volume, Lumen volume, Neointimal hyperplasia, Volume obstruction, Incomplete stent apposition, Plaque behind the stent struts</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEVICE-ORIENTED COMPOSITE ENDPOINT : Cardiac death, MI not clearly attributable to a non-target vessel, Target lesion revascularization (TLR)</measure>
    <time_frame>30 days, 6 months, 9 months, 1, 2, 3, 4, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENT-ORIENTED COMPOSITE ENDPOINT : All-cause death, Any MI (including non-target vessel territory), Any repeat revascularization (including all target and non-target vessel)</measure>
    <time_frame>30 days, 6 months, 9 months, 1, 2, 3, 4, and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STENT THROMBOSIS</measure>
    <time_frame>30 days, 6 months, 9 months, 1, 2, 3, 4, and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Supralimus(R) Sirolimus Eluting Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience V™ Everolimus Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supralimus(R) Sirolimus-Eluting Coronary Stent System</intervention_name>
    <description>Drug eluting stent implantation in the treatment of coronary artery disease.</description>
    <arm_group_label>Supralimus(R) Sirolimus Eluting Stent</arm_group_label>
    <other_name>Drug Eluting Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V™ Everolimus Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation in the treatment of coronary artery disease</description>
    <arm_group_label>Xience V™ Everolimus Eluting Stent</arm_group_label>
    <other_name>Drug Eluting Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age ≥18 years.

          2. Eligible for percutaneous coronary intervention (PCI)

          3. Acceptable candidate for CABG

          4. Clinical evidence of ischemic heart disease and/or a positive territorial functional
             study. Documented stable angina pectoris ((Canadian Cardiovascular Society (CCS)
             Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia
             (Braunwald Class IB-C, IIB-C or IIIB-C), or documented silent ischemia.

          5. The target lesion is a single de novo coronary artery lesion with ≥ 50% and &lt; 100%
             stenosis in one of the major epicardial territories (LAD, LCX or RCA). A second target
             lesion in another major epicardial vessel could be treated and this second lesion
             should fit with the inclusion/exclusion criteria and will receive the same type of
             stent.

          6. The target lesion must be covered by one study stent, preferably with a margin of 3 mm
             on each side of the lesion.

          7. The target lesion must be ≤ 22 mm in length by visual estimate.

          8. The target reference vessel diameter must be ≥ 2.5 mm and ≤ 3.5 mm.

          9. Patient or patient's legal representative has been informed of the nature of the study
             and agrees to its provisions and has provided written informed consent as approved by
             the Institutional Review Board/Ethics Committee of the clinical site.

        Exclusion Criteria:

          1. Female of childbearing potential

          2. Documented left ventricular ejection fraction (LVEF) ≤ 30%

          3. Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours
             preceding the index procedure

          4. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®, Ceruvin) or
             ticlopidine (Ticlid®), heparin, sirolimus, everolimus, stainless steel, cobalt,
             chromium, contrast agent (that cannot be adequately pre-medicated)

          5. A platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3 or a WBC &lt;3,000 cells/mm3

          6. Acute or chronic renal dysfunction (creatinine &gt;2.0mg/dl or &gt;150µmol/L)

          7. Total occlusion (TIMI 0) or TIMI 1

          8. Target vessel has evidence of thrombus

          9. Target vessel is excessively tortuous which makes it unsuitable for proper stent
             delivery and deployment

         10. Previous bare metal stenting (less than 1 year) anywhere within the target vessel

         11. Previous drug-eluting stenting anywhere within any epicardial vessel

         12. The target lesion requires treatment with a device other than PTCA prior to stent
             placement (e.g. but not limited to, directional coronary atherectomy, excimer laser,
             rotational atherectomy, etc.)

         13. Significant (&gt;50%) stenosis proximal or distal to the target lesion that might require
             revascularization or impede run-off

         14. Heavily calcified lesion and/or calcified lesion which cannot be successfully
             predilated

         15. Target lesion is located in or supplied by an arterial or venous bypass graft

         16. Ostial target lesion

         17. Target lesion involves a side branch &gt;2.0mm in diameter with an ostial disease

         18. Patient is currently participating in an investigational drug or device study,
             including its follow-up period

         19. Within 30 days prior to procedure, patient has undergone a previous coronary
             interventional procedure of any kind

         20. Within 60 days post-procedure, patient requires planned interventional treatment of
             any non-target vessel. Planned intervention of the target vessel after the index
             procedure is not allowed.

         21. Stroke or transient ischemic attack within the prior 6 months

         22. Unprotected Left Main (LM) coronary artery disease (stenosis &gt;50%)

         23. In the investigator's opinion, patient has a co-morbid condition(s) that could limit
             the patient's ability to participate in the study, compliance with follow-up
             requirements or impact the scientific integrity of the study

         24. Planned surgery within 6 months after the index procedure

         25. Life expectancy less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Patrick W Serruys, MD, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Thoraxcenter,Rotterdam,NL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Meridional</name>
      <address>
        <city>Vitaria</city>
        <state>Espirito Santo</state>
        <zip>29156-580</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Cardiologia e Radiologia Intervencionista</name>
      <address>
        <city>Goiania</city>
        <state>Goiás.</state>
        <zip>74823-470</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Diagnóstico</name>
      <address>
        <city>Campo Grande</city>
        <state>Mato Grosso do Sul</state>
        <zip>79002-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de misericórdia de Juiz de fora</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36025-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intistuto do Coracao do Triangulo</name>
      <address>
        <city>Uberlandia</city>
        <state>Minas Gerais</state>
        <zip>38400-299</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costantino Constantini</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80320-320</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incor Hospital</name>
      <address>
        <city>Brasília</city>
        <zip>70658-700</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bandeirantes</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01506-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incor Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04012-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04012-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Escorts Heart Institute &amp; Research Centre</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Devki Devi Heart and Vascular Institute</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Care Institute</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shri.Jayadeva Institute of Cardiology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560069</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.R.S Hospital</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital &amp; Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEM Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical Mission</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamilnadu</state>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjay Gandhi Post Graduate Institute of Medical Sciences</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kailash Health Care Limited</name>
      <address>
        <city>Noida</city>
        <state>Uttar Pradesh</state>
        <zip>201 301</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.M.Birla Heart Research Center</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700 027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAUH King Abdl Aziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21589</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>India</country>
    <country>Saudi Arabia</country>
  </location_countries>
  <reference>
    <citation>Dani S, Kukreja N, Parikh P, Joshi H, Prajapati J, Jain S, Thanvi S, Shah B, Dutta JP. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention. 2008 May;4(1):59-63.</citation>
    <PMID>19112780</PMID>
  </reference>
  <reference>
    <citation>Dr. A.Abhyankar; Evaluation of Safety, Efficacy and Procedural Outcomes of Extra Long Sirolimus Eluting Stent with novel polymeric technology for treatment of long de novo coronary lesions; Catheterization Cardiovascular Interventions; 3rd Nov - 2nd Dec 2006; DOI 10.1002/ccd.21033</citation>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <keyword>coronary stents</keyword>
  <keyword>angioplasty</keyword>
  <keyword>drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

